Forbion European Acquisition Corp. (FRBN) to Combine with enGene

Forbion European Acquisition Corp. (NASDAQ:FRBN) has entered into a definitive agreement to combine with biotech firm enGene. Montreal-based company enGene is developing non-viral gene therapies to treat cancers and other conditions. The combined company is expected to trade on the Nasdaq once the deal is completed in the Transaction Overview Forbion has about $133 million
Read More